血液肿瘤的精准诊治

张曦; 饶军

doi:10.16016/j.1000-5404.202008080

您当前的位置：

首页 >

文章列表页 >

血液肿瘤的精准诊治

更新时间：2026-01-09

- 血液肿瘤的精准诊治
- Precision diagnosis and treatment for hematological tumors
- 第三军医大学学报 2020年42卷第17期页码：1675-1680
- 作者机构：
- 作者简介：
  
  [ "张曦，博士，主任医师，教授，博士生导师，教育部长江学者特聘教授。担任中华医学会血液学分会常委，重庆市医学会血液病专委会主委，中国医师协会血液科医师分会常委，中国抗癌协会血液肿瘤专委会常委，中国血液病专科联盟副理事长。荣获中国肿瘤青年科学家，重庆市首席医学专家，重庆市学术技术带头人，重庆市医学领军人才，重庆市科技创新领军人才，全军创新工程学科拔尖人才，首批陆军科技英才。主持国家干细胞重点研发课题(1项)、国家自然科学基金(5项)及省部级课题共30项。获得中华医学科技奖一等奖1项、重庆市科技进步一等奖2项，省部级科技成果二等奖4项。以通信/第一作者发表SCI论文56篇。主编/副主编专著4部。研究主要聚焦“造血干细胞移植和微环境的基础与临床转化研究”。E-mail: zhangxxi@sina.com" ]
  [ "饶军，博士，主治医师，讲师。担任中国抗癌协会血液病转化委员会青年委员，重庆市中西医结合学会血液病专委会委员。陆军军医大学“苗圃工程”培养对象，发表SCI论文7篇，主持国家自然科学基金和省部级课题共3项，主要从事造血干细胞移植、淋巴瘤等恶性血液病的诊治及造血微环境及淋巴瘤的发生、发展方面的研究。E-mail: raojun1129@126.com" ]
- 基金信息：
  
  重庆市社会事业与民生保障科技创新专项(CSTC2016shms-ztzx10003)
- DOI：10.16016/j.1000-5404.202008080
  中图分类号：
- 收稿：2020-08-10，
  
  纸质出版：2020-09-15
- 稿件说明：
移动端阅览
张曦, 饶军. 血液肿瘤的精准诊治[J]. 第三军医大学学报, 2020,42(17):1675-1680.

Xi ZHANG, Jun RAO. Precision diagnosis and treatment for hematological tumors[J]. Journal of Third Military Medical University, 2020, 42(17): 1675-1680.
张曦, 饶军. 血液肿瘤的精准诊治[J]. 第三军医大学学报, 2020,42(17):1675-1680. DOI： 10.16016/j.1000-5404.202008080.

Xi ZHANG, Jun RAO. Precision diagnosis and treatment for hematological tumors[J]. Journal of Third Military Medical University, 2020, 42(17): 1675-1680. DOI： 10.16016/j.1000-5404.202008080.

摘要

Abstract

Hematological tumors are one of the most common malignant tumors with high heterogenicity originated from the hematopoietic organs

and mainly damage the hematopoietic system. Traditional treatment methods mainly include radiotherapy and chemotherapy

but their effects are limited. The development of high-throughput gene sequencing technology and molecular diagnostic technology provides a theoretical basis for the disease classification

risk stratification and individualized treatment of hematological tumors

which greatly promotes the development of targeting therapy

immunotherapy

cell therapy and hematopoietic stem cell transplantation technology

and achieves good clinical application results. Based on the patients’ clinical information and risk stratification

selecting appropriate treatment drugs and performing personalized treatment are beneficial to improve the clinical efficacy of the patient and prolong the life of the patients.

关键词

Keywords

references

DÖHNER H WEISDORF D J BLOOMFIELD C D Acute myeloid leukemia N Engl J Med 2015 373 12 1136 1152 10.1056/NEJMra1406184 DÖHNER H, WEISDORF D J, BLOOMFIELD C D. Acute myeloid leukemia[J]. N Engl J Med , 2015, 373 (12):1136-1152. DOI:10.1056/NEJMra1406184.

PERL A MARTINELLI G CORTES J Gilteritinib significantly prolongs overall survival in patients with flt3-mutated (flt3mut+) relapsed/refractory (r/r) acute myeloid leukemia (aml): results from the phase 3 admiral trial Hema Sphere 2019 3 392 393 10.1097/01.hs9.0000561784.84381.11 PERL A, MARTINELLI G, CORTES J, et al . Gilteritinib significantly prolongs overall survival in patients with flt3-mutated (flt3mut+) relapsed/refractory (r/r) acute myeloid leukemia (aml): results from the phase 3 admiral trial[J ] . Hema Sphere, 2019, 3: 392-393. DOI:10.1097/01.hs9.0000561784.84381.11.

DINARDO C D STEIN E M DE BOTTON S Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML N Engl J Med 2018 378 25 2386 2398 10.1056/NEJMoa1716984 DINARDO C D, STEIN E M, DE BOTTON S, et al . Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML[J ] . N Engl J Med, 2018, 378(25): 2386-2398. DOI :10.1056/NEJMoa1716984.

STEIN E M DINARDO C D POLLYEA D A Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Blood 2017 130 6 722 731 10.1182/blood-2017-04-779405 STEIN E M, DINARDO C D, POLLYEA D A, et al . Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J ] . Blood, 2017, 130(6): 722-731. DOI:10.1182/blood-2017-04-779405.

DINARDO C D RAUSCH C R BENTON C Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies Am J Hematol 2018 93 3 401 407 10.1002/ajh.25000 DINARDO C D, RAUSCH C R, BENTON C, et al . Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies[J ] . Am J Hematol, 2018, 93(3): 401-407. DOI:10.1002/ajh.2 5000.

BODDU P KANTARJIAN H GARCIA-MANERO G The emerging role of immune checkpoint based approaches in AML and MDS Leuk Lymphoma 2018 59 4 790 802 10.1080/10428194.2017.1344905 BODDU P, KANTARJIAN H, GARCIA-MANERO G, et al . The emerging role of immune checkpoint based approaches in AML and MDS[J ] . Leuk Lymphoma, 2018, 59(4): 790-802. DOI:10.1080/10428194.2017.1344905.

DOMBRET H SEYMOUR J F BUTRYM A International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Blood 2015 126 3 291 299 10.1182/blood-2015-01-621664 DOMBRET H, SEYMOUR J F, BUTRYM A, et al . International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts[J ] . Blood, 2015, 126(3): 291-299. DOI:10.1182/blood-2015-01-621664.

HULS G CHITU D A HAVELANGE V Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients Blood 2019 133 13 1457 1464 10.1182/blood-2018-10-879866 HULS G, CHITU D A, HAVELANGE V, et al . Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients[J ] . Blood, 2019, 133(13): 1457-1464. DOI:10.1182/blood-2018-10-879866.

CORTES J E KIM D W PINILLA-IBARZ J Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial Blood 2018 132 4 393 404 10.1182/blood-2016-09-739086 CORTES J E, KIM D W, PINILLA-IBARZ J, et al . Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial[J ] . Blood, 2018, 132(4): 393-404. DOI:10.1182/blood-2016-09-739086.

ATRASH S BANO K HARRISON B CAR-T treatment for hematological malignancies J Investig Med 2020 68 5 956 964 10.1136/jim-2020-001290 ATRASH S, BANO K, HARRISON B, et al . CAR-T treatment for hematological malignancies[J ] . J Investig Med, 2020, 68(5): 956-964. DOI:10.1136/jim-2020-001290.

MAUDE S L LAETSCH T W BUECHNER J Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia N Engl J Med 2018 378 5 439 448 10.1056/NEJMoa1709866 MAUDE S L, LAETSCH T W, BUECHNER J, et al . Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia[J ] . N Engl J Med, 2018, 378(5): 439-448. DOI:10.1056/NEJMoa1709866.

AHMAD A UDDIN S STEINHOFF M CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas Int J Mol Sci 2020 21 11 3906 10.3390/ijms21113906 AHMAD A, UDDIN S, STEINHOFF M. CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas[J]. Int J Mol Sci, 2020, 21(11): 3906. DOI:10.3390/ijms21113906.

ABREU T R FONSECA N A GONALVES N Current challenges and emerging opportunities of CAR-T cell therapies J Control Release 2020 319 246 261 10.1016/j.jconrel.2019.12.047 ABREU T R, FONSECA N A, GONALVES N, et al . Current challenges and emerging opportunities of CAR-T cell therapies[J ] . J Control Release, 2020, 319: 246-261. DOI:10.1016/j.jconrel.2019.12.047.

SCHMITZ R WRIGHT G W HUANG D W Genetics and pathogenesis of diffuse large B-cell lymphoma N Engl J Med 2018 378 15 1396 1407 10.1056/NEJMoa1801445 SCHMITZ R, WRIGHT G W, HUANG D W, et al . Genetics and pathogenesis of diffuse large B-cell lymphoma[J ] . N Engl J Med, 2018, 378(15): 1396-1407. DOI:10.1056/NEJMoa1801445.

LACY S E BARRANS S L BEER P A Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report Blood 2020 135 20 1759 1771 10.1182/blood.2019003535 LACY S E, BARRANS S L, BEER P A, et al . Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a haematological malignancy research network report[J ] . Blood, 2020, 135(20): 1759-1771. DOI:10.1182/blood.2019003535.

ROSCHEWSKI M DUNLEAVY K PITTALUGA S Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study Lancet Oncol 2015 16 5 541 549 10.1016/S1470-2045(15)70106-3 ROSCHEWSKI M, DUNLEAVY K, PITTALUGA S, et al . Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study[J ] . Lancet Oncol, 2015, 16(5): 541-549. DOI:10.1016/S1470-2045(15)70106-3.

LI Q ZHANG W LI J L Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma Biomark Res 2020 8 27 10.1186/s40364-020-00205-4 LI Q, ZHANG W, LI J L, et al . Plasma circulating tumor DNA assessment reveals KMT2D as a potential poor prognostic factor in extranodal NK/T-cell lymphoma[J ] . Biomark Res, 2020, 8: 27. DOI:10.1186/s40364-020-00205-4.

PONADER S BURGER J A Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies J Clin Oncol 2014 32 17 1830 1839 10.1200/jco.2013.53.1046 PONADER S, BURGER J A. Bruton’s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies[J]. J Clin Oncol, 2014, 32 (17):1830-1839. DOI:10.1200/jco.2013.53.1046.

ROBERTS A W DAVIDS M S PAGEL J M Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia N Engl J Med 2016 4 374 311 322 10.1056/NEJMoa1513257 ROBERTS A W, DAVIDS M S, PAGEL J M, et al . Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia[J ] . N Engl J Med, 2016, 4(374):311-322. DOI:10.1056/NEJMoa1513257.

ANSELL S M LESOKHIN A M BORRELLO I PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N Engl J Med 2015 372 4 311 319 10.1056/NEJMoa1411087 ANSELL S M, LESOKHIN A M, BORRELLO I, et al . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma[J ] . N Engl J Med, 2015, 372(4):311-319. DOI:10.1056/NEJMoa1411087.

SCHUSTER S J BISHOP M R TAM C S Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma N Engl J Med 2019 380 1 45 56 10.1056/NEJMoa1804980 SCHUSTER S J, BISHOP M R, TAM C S, et al . Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J ] . N Engl J Med, 2019, 380 (1):45-56. DOI:10.1056/NEJMoa1804980.

NEELAPU S S LOCKE F L BARTLETT N L Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 2017 377 26 2531 2544 10.1056/NEJMoa1707447 NEELAPU S S, LOCKE F L, BARTLETT N L, et al . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J ] . N Engl J Med , 2017, 377(26): 2531-2544. DOI:10.1056/NEJMoa1707447.

YOUNES A BARTLETT N L LEONARD J P Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 2010 363 19 1812 1821 10.1056/NEJMoa1002965 YOUNES A, BARTLETT N L, LEONARD J P, et al . Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas[J ] . N Engl J Med, 2010, 363(19): 1812-1821. DOI:10.1056/NEJMoa1002965.

ZAHID U AKBAR F AMARANENI A A review of autologous stem cell transplantation in lymphoma Curr Hematol Malig Rep 2017 12 3 217 226 10.1007/s11899-017-0382-1 ZAHID U, AKBAR F, AMARANENI A, et al . A review of autologous stem cell transplantation in lymphoma[J ] . Curr Hematol Malig Rep, 2017, 12(3): 217-226. DOI:10.1007/s11899-017-0382-1.

LIU Y RAO J LI J L Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China Haematologica 2019 10.3324/haematol.2019.226985 LIU Y, RAO J, LI J L, et al . Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China[J ] . Haematologica, 2019. . DOI:10.3324/haematol.2019.226985.

JOSHUA D E BRYANT C DIX C Biology and therapy of multiple myeloma Med J Aust 2019 210 8 375 380 10.5694/mja2.50129 JOSHUA D E, BRYANT C, DIX C, et al . Biology and therapy of multiple myeloma[J ] . Med J Aust, 2019, 210(8): 375-380. DOI:10.5694/mja2.50129.

CHARI A VOGL D T GAVRIATOPOULOU M Oral selinexor-dexamethasone for triple-class refractory multiple myeloma N Engl J Med 2019 381 8 727 738 10.1056/NEJMoa1903455 CHARI A, VOGL D T, GAVRIATOPOULOU M, et al . Oral selinexor-dexamethasone for triple-class refractory multiple myeloma[J ] . N Engl J Med, 2019, 381(8):727-738. DOI:10.1056/NEJMoa1903455.

DINARDO C D PRATZ K PULLARKAT V Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia Blood 2019 133 1 7 17 10.1182/blood-2018-08-868752 DINARDO C D, PRATZ K, PULLARKAT V, et al . Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J ] . Blood, 2019, 133 (1):7-17. DOI: 10.1182/blood-2018-08-868752.

PALUMBO A CHANAN-KHAN A WEISEL K Daratumumab, bortezomib, and dexamethasone for multiple myeloma N Engl J Med 2016 375 8 754 766 10.1056/NEJMoa1606038 PALUMBO A, CHANAN-KHAN A, WEISEL K, et al . Daratumumab, bortezomib, and dexamethasone for multiple myeloma[J ] . N Engl J Med, 2016, 375(8): 754-766. DOI:10.1056/NEJMoa1606038.

RAJE N BERDEJA J LIN Y Anti-BCMA CAR T- cell therapy bb2121 in relapsed or refractory multiple myeloma N Engl J Med 2019 380 18 1726 1737 10.1056/NEJMoa1817226 RAJE N, BERDEJA J, LIN Y, et al . Anti-BCMA CAR T- cell therapy bb2121 in relapsed or refractory multiple myeloma[J ] . N Engl J Med, 2019, 380(18):1726-1737. DOI:10.1056/NEJMoa1817226.

TIMMERS M ROEX G WANG Y Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen Front Immunol 2019 10 1613 10.3389/fimmu.2019.01613 TIMMERS M, ROEX G, WANG Y, et al . Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen[J ] . Front Immunol, 2019, 10:1613. DOI:10.3389/fimmu.2019.01613.

PALUMBO A CAVALLO F GAY F Autologous transplantation and maintenance therapy in multiple myeloma N Engl J Med 2014 371 10 895 905 10.1056/nejmoa1402888 PALUMBO A, CAVALLO F, GAY F, et al . Autologous transplantation and maintenance therapy in multiple myeloma[J ] . N Engl J Med, 2014, 371(10): 895-905. DOI:10.1056/nejmoa1402888.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据